British Peripheral Nerve Society

This meeting is open to BPNS members and other professionals working in relevant areas, but not to patients or members of the general public without advance permission.

Dinner following meeting on 17 Nov 2017

Start Date

End Date

Friday 17 Nov 2017 18:30 PM

Friday 17 Nov 2017 21:00 PM

Location

Queen Square, London

Details

This webpage refers only to the dinner. The dinner has been set up on the website as if it were a separate meeting.

There will be an informal dinner after the scientific meeting at a local restaurant (Salaam Namaste, 68 Millman Street, Bloomsbury, and London WC1N3EF @ 18.30) within walking distance of Queen Square. The cost of this (£40) is additional to the meeting registration and those wishing to attend dinner should register on this page and pay before 10th November so that numbers can be finalised with the restaurant.

If you wish to attend both the actual meeting and the dinner then you must register and pay twice, both on this page and on the main meeting page.

If you don't wish to attend the dinner, then don't register on this page but instead go to the main meeting page.

Lost driving licence

Jiten Mistry misplaced his driving licence at the Belfast meeting. If anyone picked it up, please could they contact him at jitenmistry@nhs.net.

Queen Square Annual Update in Neuromuscular Disorders

This course will be held from Wednesday 13th May to Friday 15th May in the Clinical Neuroscience Lecture Theatre, Lower ground, 33 Queen Square, London WC1N 3BG

DETAILS/REGISTRATION

Brain Fellowships

Applications are invited for 1 year fellowships funded by the Guarantors of Brain. These fellowships provide bridging salary support to early career clinicians based in the UK prior to obtaining a research fellowship. Further details can be found HERE

New NHSE commissioning policies for rituximab and IVIg

We are pleased to announce that, largely due to the efforts of our president Prof Lunn, rituximab is now approved for treatment of IgM paraproteinaemic demyelinating peripheral neuropathy (anti-MAG phenotype, with or without anti-MAG antibodies): 1910-rituximab-for-treatment-of-PDPN-policy-v2.pdf (england.nhs.uk). Whilst we have hitherto been able to treat some patients with rituximab by sending them to a haematologist, this was not possible if the bone marrow showed insufficient evidence of underlying lymphoplasmacytic lymphoma. These patients can now be treated, regardless of bone marrow result, either by you or by your friendly haematologist, under the new commissioning guidance.
Also thanks to Prof Lunn (alongside non-neurology colleagues), the updated IVIg commissioning policy is now available: Commissioning-Criteria-Policy-for-the-use-of-Ig-Version-Finala.pdf (mdsas.com). Newly commissioned diagnoses of relevance to peripheral nerve now include acute autoimmune autonomic ganglionopathy, and neuromyotonia.
Finally, with thanks largely to the efforts of Dr Rinaldi in Oxford, rituximab can now be used for the treatment of autoimmune nodopathies (with nodal/paranodal antibodies): NHS England » Rituximab therapy for the treatment of nodal/paranodal antibody positive inflammatory/autoimmune neuropathy in adults and postpubescent children.

More news »

Meetings

Lost driving licence

Queen Square Annual Update in Neuromuscular Disorders

Brain Fellowships

New NHSE commissioning policies for rituximab and IVIg